Company Overview of QIAGEN GmbH
QIAGEN GmbH provides sample and assay technologies for research in molecular diagnostics, applied testing, pharma, and academic research. Its products include assay technologies for pathogen detection and genetic analysis, HLA, and haplotyping; molecular diagnostic tests; gene expression and silencing solutions; genotyping solutions for genotyping analysis; sequencing and epigenetics solutions; and plant research, protein science, and whole genome amplification solutions. The company also offers QIAGEN kits for polymerase chain reaction cycling; and biomedical tissue management systems that help in sample processing and analysis. The sample technologies are used to isolate and process DNA, R...
QIAGEN Strasse 1
Founded in 1984
49 2103 29 12000
49 2103 29 22000
Key Executives for QIAGEN GmbH
Senior Vice President of Global Sales and Managing Director
Senior Vice President of Global Research & Development and Managing Director
Vice President of Consumer Marketing Communications
Vice President of Global Human Resources
Compensation as of Fiscal Year 2014.
QIAGEN GmbH Key Developments
QIAGEN GmbH Presents at Berenberg Diagnostics Conference, May-15-2014
Feb 22 14
QIAGEN GmbH Presents at Berenberg Diagnostics Conference, May-15-2014 . Venue: London, United Kingdom. Speakers: Peer M. Schatz, Chief Executive Officer and Managing Director.
QIAGEN GmbH Presents at Berenberg and Goldman Sachs Second Annual German Corporate Conference, Sep-24-2013 03:45 PM
Mar 28 13
QIAGEN GmbH Presents at Berenberg and Goldman Sachs Second Annual German Corporate Conference, Sep-24-2013 03:45 PM. Venue: Dolce Munich Unterschleissheim, Andreas-Danzer-Weg 1, 85716 Unterschleissheim, Munich, Germany. Speakers: Roland Sackers, Chief Financial Officer.
QIAGEN and Eli Lilly and Co. Partner to Develop and Commercialize Companion Diagnostics
Feb 16 13
QIAGEN and Eli Lilly and Co. have signed a master collaboration agreement to develop and commercialize companion diagnostics for combining with Lilly investigational and approved medicines across all therapeutic areas. The contract has been signed due to QIAGEN and Lilly's past work together. The companion diagnostics opens up a patient's molecular information to direct treatment decisions of particular cancers or other diseases. The agreement's financial terms are not disclosed yet. The agreement offers a structure to Lilly and QIAGEN to partner on future projects, focusing on bringing Lilly medicines paired with QIAGEN diagnostics in market. Also, it highlights QIAGEN's position in collaboration with global pharmaceutical companies to provide advantageous of personalized medicine. Earlier, QIAGEN and Lilly have partnered on companion diagnostics that were created to run on QIAGEN's Rotor-Gene Q system.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries